Hazard identification and risk assessment for biologics targeting the immune system.
Biologic pharmaceuticals include a variety of products, such as monoclonal antibodies, fusion proteins and cytokines. Products in those classes include immunomodulatory biologics, which are intended to enhance or diminish the activity of the immune system. Immunomodulatory biologics have been approved by the U.S. FDA for a variety of indications, including cancer and inflammatory conditions. Prior to gaining approval for marketing, sponsoring companies for all types of products must demonstrate a product's safety in toxicology studies conducted in animals and show safety and efficacy in clinical trials conducted in patients. The overall goal of toxicology studies, which applies to immunomodulatory and other product types, is to identify the hazards that products pose to humans. Because biologics are generally highly selective for specific targets (receptors/epitopes), conducting toxicology studies in animal models with the target is essential. Such animals are referred to as pharmacologically relevant. Endpoints routinely included in toxicology studies, such as hematology, organ weight and histopathology, can be used to assess the effect of a product on the structure of the immune system. Additionally, specialized endpoints, such as immunophenotyping and immune function tests, can be used to define effects of immunomodulatory products on the immune system. Following hazard identification, risks posed to patients are assessed and managed. Risks can be managed through clinical trial design and risk communication, a practice that applies to immunomodulatory and other product types. Examples of risk management in clinical trial design include establishing a safe starting dose, defining the appropriate patient population and establishing appropriate patient monitoring. Risk communication starts during clinical trials and continues after product approval. A combination of hazard identification, risk assessment and risk management allows for drug development to proceed with minimum risks to patients.
Weir
Andrea B
AB
Charles River Laboratories, Navigators, Reno, Nevada 89431, USA. andrea.weir@us.crl.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use* / Q000633:toxicity*; D002986:Clinical Trials as Topic; D004304:Dosage Forms; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D007154:Immune System Diseases / Q000628:therapy; D051379:Mice; D023421:Models, Animal; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D018570:Risk Assessment / Q000706:statistics & numerical data / Q000639:trends; D012308:Risk Management / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data / Q000639:trends; D017751:Safety Management / Q000706:statistics & numerical data / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D001688:Biological Products; D004304:Dosage Forms